As described, negative regulation of this pathway employing PD-1-or PD-L1-targeting anti-bodies has become a promising plan with preferred clinical responses in numerous solid tumors like RCC [120, 121]. This evidence concerns the gene PDCD1 and renal cell carcinoma.